Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome.
Five patients with idiopathic orthostatic hypotension, two of whom had central nervous system manifestations (Shy-Drager syndrome), were treated with midodrine, an investigational alpha-adrenergic agonist, in a dosage of 2.5 to 5 mg three times daily. Significant improvement was observed in the standing systolic and diastolic blood pressures at the end of 1 week of therapy in all patients and has been maintained for 10 to 15 months in all patients. No symptomatic side effects were noted. Supine systolic hypertension occurred in two patients and was treated with small doses of metoprolol.
D000328:Adult; D000368:Aged; D001342:Autonomic Nervous System Diseases / Q000188:drug therapy*; D001794:Blood Pressure; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008879:Midodrine / Q000627:therapeutic use*; D011187:Posture; D012791:Shy-Drager Syndrome / Q000188:drug therapy*
D004983:Ethanolamines; D008879:Midodrine